Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07GDN
|
|||
| Former ID |
DCL000252
|
|||
| Drug Name |
Torcetrapib
|
|||
| Synonyms |
Torcetrapib [USAN]; CP 529414; CP-529414; CP-529,414; Torcetrapib (USAN/INN); Ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinoline-1-carboxylate; Ethyl (2R,4S)-4-{[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino}-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; Ethyl (2R,4S)-4-((3,5-bis(trifluoromethyl)benzyl)(methoxycarbonyl)amino)-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate; (2R,4S)-4-((3,5-Bis-trifluoromethylbenzyl)methoxycarbonylamino)-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperlipidaemia [ICD-11: 5C80; ICD-10: E78.4, E78.5] | Discontinued in Phase 2 | [1] | |
| Peripheral vascular disease [ICD-11: BD4Z; ICD-10: I73, I73.9] | Discontinued in Phase 2 | [1] | ||
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H25F9N2O4
|
|||
| Canonical SMILES |
CCC1CC(C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)OC
|
|||
| InChI |
1S/C26H25F9N2O4/c1-4-18-12-21(19-11-15(24(27,28)29)6-7-20(19)37(18)23(39)41-5-2)36(22(38)40-3)13-14-8-16(25(30,31)32)10-17(9-14)26(33,34)35/h6-11,18,21H,4-5,12-13H2,1-3H3/t18-,21+/m1/s1
|
|||
| InChIKey |
CMSGWTNRGKRWGS-NQIIRXRSSA-N
|
|||
| CAS Number |
CAS 262352-17-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10253568, 12015506, 14838441, 14936147, 46234611, 47207853, 49742809, 50070566, 50071185, 52291545, 57348599, 103650003, 104147079, 113442144, 126680820, 127337898, 127337899, 127337900, 127337901, 131307890, 134338910, 135114738, 137249059, 140213212, 144080642, 152159602, 152344056, 162009744, 162011530, 162205057, 162224233, 163203030, 163884619, 164194110, 164339263, 164765659, 170502450, 174007268, 174528577, 179150237, 185978179, 198955213, 223395254, 223666373, 223704932, 223788005, 226432919, 241376851, 246105868, 251963040
|
|||
| ChEBI ID |
CHEBI:49203
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cholesteryl ester transfer protein (CETP) | Target Info | Inhibitor | [2], [3], [4] |
| Panther Pathway | CCKR signaling map ST | |||
| Reactome | LDL-mediated lipid transport | |||
| HDL-mediated lipid transport | ||||
| WikiPathways | Statin Pathway | |||
| Lipid digestion, mobilization, and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015157) | |||
| REF 2 | Safety and tolerability of dalcetrapib. Am J Cardiol. 2009 Jul 1;104(1):82-91. | |||
| REF 3 | A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future develop... Biochem Pharmacol. 2009 Aug 15;78(4):315-25. | |||
| REF 4 | The end of the road for CETP inhibitors after torcetrapib Curr Opin Cardiol. 2009 Jul;24(4):364-71. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.